Correspondence 0001193125-22-287795 from IN8BIO, INC. (INAB) (CIK 0001740279) (INAB)
IN8BIO, INC. (INAB) (CIK 0001740279)
Date: Nov. 17, 2022 · CIK: 0001740279 · Accession: 0001193125-22-287795
AI Filing Summary & Sentiment
File numbers found in text: 333-268288
Show Raw Text
CORRESP 1 filename1.htm CORRESP IN8BIO, INC. 350 5th Avenue, Suite 5330 New York, New York 10118 November 17, 2022 VIA EDGAR Securities and Exchange Commission Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: IN8bio, Inc. Registration Statement on Form S-3 (CIK No. 0001740279) File No. 333-268288 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, IN8bio, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective as of 4:00 p.m. Eastern time, on November 21, 2022, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff. Once the Registration Statement has been declared effective, please confirm that event with Jaime L. Chase of Cooley LLP by phone at (202) 728-7096 or by e-mail at jchase@cooley.com. [Signature page follows] Very truly yours, IN8bio, Inc. /s/ William Ho By: William Ho Title: President and Chief Executive Officer [Signature Page to Acceleration Request]